ProfileGDS5678 / 1440528_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 11% 11% 11% 11% 11% 10% 11% 11% 11% 11% 11% 11% 11% 11% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.3002511
GSM967853U87-EV human glioblastoma xenograft - Control 22.2749311
GSM967854U87-EV human glioblastoma xenograft - Control 32.2819411
GSM967855U87-EV human glioblastoma xenograft - Control 42.220411
GSM967856U87-EV human glioblastoma xenograft - Control 52.238711
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.3023210
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.2908711
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.2537711
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.2575511
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.2740111
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.2605611
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.2608911
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.2753311
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.266611